Tag - CUE

Executive Moves

Dr. Usman Azam appointed president and CEO of Cue

Cue Biopharma (NASDAQ: CUE) has announced that Usman Azam, MD has been appointed president and CEO of Cue Biopharma, effective today. Daniel Passeri will transition from his current role as CEO to one of strategic...

September 30, 2025

Markets

Stifel starts Cue Biopharma at buy; PT $21

Stifel initiated coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $21 price target. The stock closed at $16.60, up $1.53, on April 8. “We believe the Immuno-STAT platform from which the company’ wholly...

April 9, 2020

Markets

BTIG starts Cue Biopharma at buy; PT $26

BTIG launched coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $26 price target. The stock closed at $15.51 on Jan. 27. Cue Biopharma exploits signals naturally provided by dendritic cells (DCs) to...

January 28, 2020

Developments

FDA accepts Cue Biopharma IND for HPV-associated cancer candidate

Cue Biopharma’s (NASDAQ:CUE) IND for CUE-101, an immuno-oncology candidate for human papilloma virus (HPV)-associated cancers, had been accepted by the FDA. The majority of HPV-associated cancers are caused by the HPV16...

May 16, 2019

Tag - CUE

Dr. Usman Azam appointed president and CEO of Cue

Stifel starts Cue Biopharma at buy; PT $21

BTIG starts Cue Biopharma at buy; PT $26

FDA accepts Cue Biopharma IND for HPV-associated cancer candidate

Subscribe